Livzon Pharma Reports No Share Capital Changes in October; Confirms Public Float Compliance

Bulletin Express
11/02

Livzon Pharmaceutical Group Inc. released its Monthly Return for Equity Issuer for the period ended 31 October 2026, showing stable share capital across both its Hong Kong–listed H shares and Shenzhen-listed A shares.

Total authorised share capital stood at 887.91 million shares, split between 299.81 million H shares and 588.10 million A shares, each with a par value of RMB 1.00. The figures were unchanged from the prior month.

Issued share volumes also remained flat. H shares in issue totalled 299.81 million, while A shares totalled 588.10 million; the company held no treasury shares in either class. Livzon Pharma confirmed that its H-share public float continues to meet the Hong Kong Stock Exchange’s 5 percent minimum requirement for PRC issuers with other listed shares.

The filing noted no activity in share options, warrants, convertible securities, or other equity instruments during the month. All statutory and regulatory obligations associated with the company’s share capital were declared satisfied by the company secretary, Liu Ning, upon submission of the report on 2 November 2026.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10